Rapalogix Health publishes clinical study on Re-Q Longevity serum
Rapalogix Health announced the publication of a peer-reviewed, randomized, double-blind, vehicle-controlled 12-week study of RLX-201, the active molecule in Re-Q Longevity Face Serum, in the Journal of Cosmetic Dermatology. The trial was conducted at Dermatology Consulting Services in High Point, No
<p>Rapalogix Health announced the publication of a peer-reviewed, randomized, double-blind, vehicle-controlled 12-week study of RLX-201, the active molecule in Re-Q Longevity Face Serum, in the Journal of Cosmetic Dermatology. The trial was conducted at Dermatology Consulting Services in High Point, No</p>